Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945944 | 0.80 | CHRM1 (0.41) | MEN1KMT2ACHRM1MTNR1AMTNR1B | |
| SCHEMBL27585696 | 0.77 | CHRM1 (0.36) | MEN1KMT2ACHRM1MTNR1AMTNR1B | |
| SCHEMBL5092064 | 0.77 | ANPEP (0.41) | CHRM1MTNR1AMTNR1BGAALMNA | |
| SCHEMBL1500501 | 0.77 | LTA4H (0.43) | CHRM1PPARGPPARALTA4H | |
| SCHEMBL950050 | 0.77 | PPARG (0.41) | CHRM1MTNR1AMTNR1BPPARGPPARA | |
| SCHEMBL11578028 | 0.74 | ALDH1A1 (0.42) | MEN1KMT2ACHRM1ALDH1A1LTA4H | |
| SCHEMBL11617114 | 0.74 | ALDH1A1 (0.42) | MEN1KMT2ACHRM1ALDH1A1LTA4H | |
| SCHEMBL8907429 | 0.74 | ALDH1A1 (0.42) | MEN1KMT2ACHRM1ALDH1A1LTA4H | |
| SCHEMBL4963146 | 0.72 | MTNR1A (0.38) | MEN1KMT2ACHRM1MTNR1AMTNR1B | |
| SCHEMBL7661580 | 0.72 | LTA4H (0.39) | MEN1KMT2ACHRM1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897392-A | Aqueous solid phase peptide synthesis | 多肽实验室(PPL)控股公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20130267681-A1 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES | THE UNIVERSITY OF READING (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012020231-A1 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES | THE UNIVERSITY OF READING (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-7803351-B2 | Blood brain barrier permeation peptides | WASHINGTON UNIVERSITY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090011981-A1 | Novel Inhibitors of Angiogenesis | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-08 | — | — | US | disclosed |
| US-7399826-B1 | Peptide for promoting healing of fractures | ALI SADAT M | 2008-07-15 | — | — | US | disclosed |
| EP-1812468-A2 | PLATELET FACTOR 4 VARIANT 1 (PF4VAR1) RELATED INHIBITORS OF ANGIOGENESIS | K.U.Leuven Research & Development (BE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006026184-A9 | BLOOD BRAIN BARRIER PERMEATION PEPTIDES | UNIV WASHINGTON (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006029487-A2 | PLATELET FACTOR 4 VARIANT 1 (PF4VAR1) RELATED INHIBITORS OF ANGIOGENESIS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006026184-A2 | BLOOD BRAIN BARRIER PERMEATION PEPTIDES | WASHINGTON UNIVERSITY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060039859-A1 | Blood brain barrier permeation peptides | WASHINGTON UNIVERSITY | 2006-02-23 | — | — | US | disclosed |
| WO-2005041998-A1 | PEPTIDE FOR PROMOTING HEALING OF FRACTURES | ALI SADAT M (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-0541340-B1 | Biopolymer synthesis apparatus and method | PERKIN ELMER CORP (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5462748-A | Biopolymer synthesis apparatus and method | APPLIED BIOSYSTEMS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0541340-A2 | Biopolymer synthesis apparatus and method | THE PERKIN-ELMER CORPORATION (US) | 1993-05-12 | — | — | EP | disclosed |
| US-4477660-A | 7-(S)-Acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0109301-A2 | 7-(S)-acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039859-A1 | Blood brain barrier permeation peptides | APP, FABP7, TAP1 | MEN1 813/4885KMT2A 4547/4885CHRM1 2236/4885 |
| US-20130267681-A1 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES | PTMS, DNPEP, TAC3 | MEN1 2130/4885KMT2A 3447/4885CHRM1 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.